Vaxxinity, Inc.
VAXX · OTC
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $66 | $557 |
| % Growth | – | -100% | -88.2% | – |
| Cost of Goods Sold | $2,234 | $1,684 | $1,937 | $52 |
| Gross Profit | -$2,234 | -$1,684 | -$1,871 | $505 |
| % Margin | – | – | -2,834.8% | 90.7% |
| R&D Expenses | $33,665 | $47,627 | $71,379 | $20,570 |
| G&A Expenses | $22,386 | $28,352 | $51,825 | $12,217 |
| SG&A Expenses | $22,386 | $28,352 | $51,825 | $12,217 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$1,684 | $0 | $0 |
| Operating Expenses | $56,051 | $74,295 | $123,204 | $32,787 |
| Operating Income | -$58,285 | -$75,979 | -$125,075 | -$32,282 |
| % Margin | – | – | -189,507.6% | -5,795.7% |
| Other Income/Exp. Net | $1,351 | $757 | -$12,100 | -$7,675 |
| Pre-Tax Income | -$57 | -$75,222 | -$137,175 | -$39,957 |
| Tax Expense | $0 | -$12 | $0 | $0 |
| Net Income | -$57 | -$75,210 | -$137,175 | -$39,957 |
| % Margin | – | – | -207,840.9% | -7,173.6% |
| EPS | -0.001 | -0.6 | -1.09 | -0.32 |
| % Growth | 99.9% | 45% | -240.6% | – |
| EPS Diluted | -0.001 | -0.6 | -1.09 | -0.32 |
| Weighted Avg Shares Out | 126,509 | 125,939 | 125,392 | 125,453 |
| Weighted Avg Shares Out Dil | 126,508 | 125,939 | 125,392 | 125,453 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2,090 | $1,259 | $9 | $0 |
| Interest Expense | $696 | $514 | $840 | $1,181 |
| Depreciation & Amortization | $2,234 | $1,684 | $1,102 | $717 |
| EBITDA | -$54,004 | -$73,024 | -$135,233 | -$38,058 |
| % Margin | – | – | -204,898.5% | -6,832.7% |